Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients

Journal:
Circulation
Published:
Affiliations:
18
Authors:
29
Institutions Authors Share
AstraZeneca Sweden, Sweden
19.000000
19.000000
0.66
Dogma Therapeutics, United States of America (USA)
3.000000
0.10
AstraZeneca United States, United States of America (USA)
3.000000
0.10
AstraZeneca Gaithersburg, MD, United States of America (USA)
2.000000
0.07
AstraZeneca, United Kingdom (UK)
2.000000
0.07